PMID- 12437640
OWN - NLM
STAT- MEDLINE
DCOM- 20030122
LR  - 20190705
IS  - 0007-1048 (Print)
IS  - 0007-1048 (Linking)
VI  - 119
IP  - 3
DP  - 2002 Dec
TI  - rHuEpo administration in patients with low-risk myelodysplastic syndromes: 
      evaluation of erythroid precursors' response by fluorescence in situ 
      hybridization on May-Grunwald-Giemsa-stained bone marrow samples.
PG  - 652-9
AB  - The issue of whether, in patients affected by myelodysplastic syndromes (MDS), 
      haematological response to cytokines, particularly to recombinant human 
      erythropoietin (rHuEpo), is a phenomenon related to the stimulation of normal 
      haemopoietic cells or to the differentiation of cells belonging to the abnormal 
      clone remains an open question. To assess the pattern of response to rHuEpo 
      treatment of bone marrow (BM) cells, we evaluated in 13 low-risk MDS patients 
      with known cytogenetic abnormalities the number of cytogenetically normal and 
      abnormal cells by conventional cytogenetic analysis (CCA) and by a fluorescence 
      in situ hybridization (FISH) technique, enabling the simultaneous visualization 
      of FISH chromosomal abnormalities in morphologically and immunophenotypically 
      identifiable BM elements. Patients responding to rHuEpo presented a lower number 
      of abnormal metaphases at diagnosis in comparison with patients who did not 
      respond (22.74% vs 76.23%, P = < 0.001). This was confirmed by the combined 
      morphological FISH analysis, showing that, before treatment, BM samples from 
      patients responding to rHuEpo had a lower proportion of both FISH abnormal 
      erythroid (36.48% vs 66.93%, P = 0.002) and myeloid (40.76% vs 67.70%, P = 0.014) 
      elements than unresponsive patients. After rHuEpo treatment, responding patients 
      presented a significantly lower proportion of FISH abnormal erythroid precursors 
      than observed before treatment (16.93%vs 36.48%, P = 0.017). Likewise, in 
      responding patients, a significantly lower proportion of FISH abnormal erythroid 
      elements (16.93% vs 66.30%, P < 0.001) was detected in comparison with 
      unresponsive patients. These findings provide evidence that, in low-risk MDS 
      patients with known cytogenetic abnormalities, response to rHuEpo may be due to 
      the proliferation of karyotypically normal erythroid precursors, possibly 
      representing residual normal erythroid elements.
FAU - Rigolin, Gian Matteo
AU  - Rigolin GM
AD  - Section of Haematology, Department of Biomedical Sciences, University of Ferrara, 
      Italy. sse@dns.unife.it
FAU - Porta, Matteo Della
AU  - Porta MD
FAU - Bigoni, Renato
AU  - Bigoni R
FAU - Cavazzini, Francesco
AU  - Cavazzini F
FAU - Ciccone, Maria
AU  - Ciccone M
FAU - Bardi, Antonella
AU  - Bardi A
FAU - Cuneo, Antonio
AU  - Cuneo A
FAU - Castoldi, Gianluigi
AU  - Castoldi G
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Br J Haematol
JT  - British journal of haematology
JID - 0372544
RN  - 0 (Recombinant Proteins)
RN  - 11096-26-7 (Erythropoietin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Erythroid Precursor Cells/pathology
MH  - Erythropoiesis/drug effects
MH  - Erythropoietin/*therapeutic use
MH  - Female
MH  - Humans
MH  - In Situ Hybridization, Fluorescence/methods
MH  - Male
MH  - Middle Aged
MH  - Myelodysplastic Syndromes/*drug therapy/pathology
MH  - Recombinant Proteins
MH  - Risk Factors
EDAT- 2002/11/20 04:00
MHDA- 2003/01/23 04:00
CRDT- 2002/11/20 04:00
PHST- 2002/11/20 04:00 [pubmed]
PHST- 2003/01/23 04:00 [medline]
PHST- 2002/11/20 04:00 [entrez]
AID - 3867 [pii]
AID - 10.1046/j.1365-2141.2002.03867.x [doi]
PST - ppublish
SO  - Br J Haematol. 2002 Dec;119(3):652-9. doi: 10.1046/j.1365-2141.2002.03867.x.